-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Tg8Mbf6XZwGh5HUq9iazeIk+wCDJQVBuanbyJb9EE3JipqDUAfWWzMe0BrDuQzKv dwF3nvFOz0Ja0GRT4iYqrQ== /in/edgar/work/20000630/0000950103-00-000802/0000950103-00-000802.txt : 20000920 0000950103-00-000802.hdr.sgml : 20000920 ACCESSION NUMBER: 0000950103-00-000802 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20000630 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LABORATORY CORP OF AMERICA HOLDINGS CENTRAL INDEX KEY: 0000920148 STANDARD INDUSTRIAL CLASSIFICATION: [8071 ] IRS NUMBER: 133757370 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-43489 FILM NUMBER: 666051 BUSINESS ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 BUSINESS PHONE: 3362291127 MAIL ADDRESS: STREET 1: 358 S MAIN ST STREET 2: 4225 EXECUTIVE SQUARE, SUITE 800 CITY: BURLINGTON STATE: NC ZIP: 27215 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL HEALTH LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19940314 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROCHE HOLDINGS INC CENTRAL INDEX KEY: 0000904566 STANDARD INDUSTRIAL CLASSIFICATION: [0000 ] IRS NUMBER: 510304944 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 410 S STATE STREET CITY: DOVER STATE: DE ZIP: 19901 BUSINESS PHONE: 2124504336 MAIL ADDRESS: STREET 1: 410 S STATE ST CITY: DOVER STATE: DE ZIP: 19901 SC 13D/A 1 0001.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ----------------------- SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2) LABORATORY CORPORATION OF AMERICA HOLDINGS - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, $0.10 PAR VALUE - -------------------------------------------------------------------------------- (Title of Class of Securities) 50540R 40 9 - -------------------------------------------------------------------------------- (CUSIP Number) Peter R. Douglas, Esq. Davis Polk & Wardwell 450 Lexington Avenue New York, NY 10017 Tel. No.: (212) 450-4000 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 26, 27, 29, 2000 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on the following pages) (Page 1 of 9 Pages) Schedule 13D - -------------------------------------------------------------------------------- - --------------------- ----------------------- CUSIP No. 5054OR 40 9 13D Page 2 of 9 Pages - --------------------- ----------------------- 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Roche Holdings, Inc. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [X] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e). [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 15,089,742 shares of Common Stock NUMBER OF See Items 4 and 5 below. SHARES ------------------------------------------------------------ BENEFICIALLY 8 SHARED VOTING POWER N/A OWNED BY ------------------------------------------------------------ EACH 9 SOLE DISPOSITIVE POWER 15,089,742 shares of Common Stock REPORTING See Items 4 and 5 below. PERSON WITH ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER N/A - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,089,742 shares of Common Stock See Items 4 and 5 below. - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 44.0% of Common Stock See Items 4 and 5 below. - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO, HC - -------------------------------------------------------------------------------- (Page 2 of 9 Pages) The following information amends and supplements the Schedule 13D dated April 28, 1995, as previously amended (as so amended, the "Schedule 13D"). Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D. Item 4. Purpose of Transaction On June 26, 2000, Holdings sold 500,000 shares of Common Stock in a brokerage transaction at a price of $72.30 per share, on June 27, 2000, Holdings sold 300,000 shares of Common Stock in a brokerage transaction at a price of $72.25 per share and on June 29, 2000, Holdings sold 1,700,000 shares of Common Stock in a brokerage transaction at a price of $75.67 per share. Item 5. Interest in Securities of the Issuer. (a) After giving effect to the sales described in Item 4, Holdings beneficially owns 15,089,742 shares of Common Stock, including 11,456,816 shares of Common Stock issuable upon conversion of the 6,301,255 shares of Series B Preferred Stock owned by Holdings. Based upon information provided by the Company as of June 6, 2000, the 15,089,742 shares of Common Stock beneficially owned by Holdings represent approximately 44.0% of the Common Stock outstanding (assuming conversion of the Company's preferred stock). (b) Except as set forth herein, no transactions in the Common Stock have been effected during the past 60 days by the Reporting Persons, any other person controlling any of the Reporting Persons or, to the best of the knowledge of the Reporting Persons, any of the persons named in Schedules A, B and C hereto, except that as described in Item 4, on June 26, 2000, Holdings sold an aggregate of 500,000 shares of Common Stock in a brokerage transaction at a price of $72.30 per share, on June 27, 2000, Holdings sold an aggregate of 300,000 shares of Common Stock in a brokerage transaction at a price of $72.25 per share and on June 29, 2000, Holdings sold an aggregate of 1,700,000 shares of Common Stock in a brokerage transaction at a price of $75.67 per share. Item 7. Material to be Filed as Exhibits 1. Executive Officers and Directors of Holdings, Finance and Roche Holding. (Page 3 of 9 Pages) SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate. Dated: June 30, 2000 ROCHE HOLDINGS, INC. By: /s/ Marcel Kohler ----------------------------------- Name: Marcel Kohler Title: Vice President, Controller and Secretary (Page 4 of 9 Pages) Index to Exhibits Exhibit 99.1: Executive Officers and Directors of Holdings, Finance and Roche Holding. (Page 5 of 9 Pages) EX-99.1 2 0002.txt EXHIBIT 99.1 SCHEDULE A Executive Officers and Directors (*) of Roche Holdings, Inc. The names of the Directors and the names and titles of the Executive Officers of Roche Holdings, Inc. and their business addresses and principal occupations are set forth below. If no address is given, the Director's or Executive Officer's business address is that of Roche Holding Ltd which is Grenzacherstrasse 124, 4002 Basel, Switzerland. Unless otherwise indicated, each occupation set forth opposite an individual's name refers to Roche Holding Ltd and each individual is a Swiss citizen. Name, Business Address Present Principal Occupation - ---------------------- ---------------------------- * Dr. h.c. Fritz Gerber.....................Chairman of the Board and President (President) * Dr. Dr. h.c. Henri B. Meier...............Chief Financial Officer (Vice President Finance and Treasurer) Marcel Kohler...............................(Vice President Controller and (Vice President, Controller and Secretary) Secretary of Roche Holdings, Inc.) One Commerce Center, Suite 1050 Wilmington, DE 19801 (Page 6 of 9 Pages) SCHEDULE B Executive Officers and Directors (*) of Roche Finance Ltd The names of the Directors and the names and titles of the Executive Officers of Roche Finance Ltd and their business addresses and principal occupations are set forth below. If no address is given, the Director's or Executive Officer's business address is that of Roche Holding Ltd, which is Grenzacherstrasse 124, 4002 Basel, Switzerland. Unless otherwise indicated, each occupation set forth opposite an individual's name refers to Roche Holding Ltd and each individual is a Swiss citizen. Name, Business Address Present Principal Occupation - ---------------------- ---------------------------- *Dr. h.c. Fritz Gerber................Chairman of the Board and President (President) * Dr. Franz B. Humer..................Chief Executive Officer * Dr. Dr. h.c. Henri B. Meier.........Chief Financial Officer (Page 7 of 9 Pages) SCHEDULE C Executive Officers and Directors of Roche Holding Ltd The names of the Directors and the names and titles of the Executive Officers of Roche Holding Ltd and their business addresses and principal occupations are set forth below. If no address is given, the Director's or Executive Officer's business address is that of Roche Holding Ltd, which is Grenzacherstrasse 124, 4002 Basel, Switzerland. Unless otherwise indicated, each occupation set forth opposite an individual's name refers to Roche Holding Ltd and each individual is a Swiss citizen, except that Mr. Brabeck-Letmathe is an Austrian citizen, Mr. von Prondzynski is a German citizen and Mr. Burns and Professor Knowles are citizens of the United Kingdom. Board of Directors Dr. h.c. Fritz Gerber Chairman Dr. Andres F. Leuenberger Vice-Chairman Dr. Rolf Hanggi Vice-Chairman Dr. Franz B. Humer Delegate Mr. Peter Brabeck-Letmathe Chief Executive Officer Nestle SA of Nestle Avenue Nestle, CH-1800 Verey Mr. Andre Hoffmann Businessman La Massellaz CH-1126 Vaux sus Morges Professor Kurt Jenny Attorney-at-law Aeschengraben 18 P.O. Box 3309 CH-4002 Basel Dr. Dr. h.c. Henri B. Meier Chief Financial Officer of Roche Holding Ltd. Dr. Andreas Oeri Surgeon Praxisgemeinschaft Clarahof Clarahofweg 19a CH-4005 Basel Professor Charles Weissmann University professor Neurogenetics Unit Imperial College School of Medicine at St. Mary's Hospital Norfolk Place London W1H 1TJ Great Britain Dr. Gottlieb A. Keller Secretary to the Board of Directors (Page 8 of 9 Pages) Executive Committee Dr. Franz B. Humer Chairman, Head of Pharmaceuticals Division Dr. Dr. h.c. Henri B. Meier Finance Mr. Heino von Prondzynski Diagnostics Division Dr. Markus Altwegg Vitamins and Fine Chemicals Division Mr. William M. Burns Pharma International Operations Professor Jonathan Knowles Global Pharmaceutical Research Dr. Daniel Villiger Corporate Services Mr. Pierre Jaccoud Secretary to the Executive Committee (Page 9 of 9 Pages) -----END PRIVACY-ENHANCED MESSAGE-----